Xenograft are the cells of one species transplanted to another species.
Large randomized clinical trials can uncover biomarkers that indicate which cancer treatments are likely to work best for individual patients. But it's been challenging to find these biomarkers in rarer cancers where such robust data aren't available.
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular research image
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking it, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Cell.
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.
University of Alabama at Birmingham researchers will receive $17.8 million in federal funding to attack a key "knowledge gap" in human immunology -- how the B cells and antibody-secreting cells that reside in tissues and organs differ from those found in blood.
For many years, radioactive iodine which emits beta rays has been used for treatment of thyroid cancer. Generally, 5-year survival rates may exceed 90%.
Of all gastrointestinal cancers, pancreatic cancer is one of the most aggressive. Because of this, it has a very low 5-year survival rate of just 5% and a median survival time below 6 months. Additionally, treatment is difficult, with only surgery shown to provide a cure. However, the vast majority of patients have tumors that cannot be removed surgically or their cancer is too advanced or spread too far to be treatable.
Like cartographers completing a map, investigators have identified multiple new subtypes of the most common childhood cancer--research that will likely improve the diagnosis and treatment of high-risk patients.
St. Jude Children's Research Hospital today announced the availability of one of the world's largest collections of leukemia samples from children and adults.
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.
Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer.
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.
Emerging cancer nanotechnology enables target-delivery of substantial payloads of drugs to cancer sites with concomitant reduction of side-effects due to the lesser accumulation in the critical organs.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.
Researchers at Columbia University Irving Medical Center have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.
Glioblastoma is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.